Talquetamab can bind to GPRC5D, a biomarker associated with high-risk myeloma, and CD3, and induces T-cell mediated death of myeloma cells expressing GPRC5D via recruitment and maturation of T-cells [305]. The gene discussed is GPRC5D; the disease is plasma cell myeloma.